臨床婦人科産科77巻2号

2023年03月発行

今月の臨床 子宮体がん診療の最前線―最新分類から治療法まで

薬物療法

メトホルミンを併用した妊孕性温存療法

著者： 三橋暁¹

所属機関： ¹獨協医科大学産科婦人科学教室

ページ範囲：P.269 - P.275

文献概要

●妊孕性温存を希望する若年の子宮体がんおよび子宮内膜異型増殖症は，多囊胞性卵巣症候群や肥満・インスリン抵抗性を有する頻度が高く，MPAを用いた妊孕性温存療法にメトホルミンの併用効果が期待される．

●メトホルミンはMPA投与時の体重増加や耐糖能悪化を予防する可能性がある．

●現在，MPAを用いた妊孕性温存療法にメトホルミンを併用する医師主導治験が行われており，その結果が待たれる．

参考文献

1）Gunderson CC, et al : Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma : a systematic review. Gynecol Oncol 125 : 477-482, 2012

2）Gallos ID, et al : Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia : a systematic review and metaanalysis. Am J Obstet Gynecol 207 : 266.e1-266.e12, 2012

3）Evans JM, et al : Metformin and reduced risk of cancer in diabetic patients. BMJ 330 : 1304-1305, 2005

4）Pernicova I, et al : Metformin--mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol 10 : 143-156, 2014

5）Alghandour R, et al : Repurposing metformin as anticancer drug : randomized controlled trial in advanced prostate cancer（MANSMED）. Urol Oncol 39 : 831.e1-831.e10, 2021

6）Kordes S, et al : Metformin in patients with advanced pancreatic cancer : a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 16 : 839-847, 2015

7）Goodwin PJ, et al : Effect of metformin vs placebo on invasive disease-free survival in patients with breast cancer : the MA.32 randomized clinical trial. JAMA 327 : 1963-1973, 2022

8）Renehan AG, et al : Body-mass index and incidence of cancer : a systematic review and meta-analysis of prospective observational studies. Lancet 371 : 569-578, 2008

9）Mitsuhashi A, et al : Prospective evaluation of abnormal glucose metabolism and insulin resistance in patients with atypical endometrial hyperplasia and endometrial cancer. Support Care Cancer 25 : 1495-1501, 2017

10）Ward KK, et al : Cardiovascular disease is the leading cause of death among endometrial cancer patients. Gynecol Oncol 126 : 176-179, 2012

11）Chu D, et al : Effect of metformin use on the risk and prognosis of endometrial cancer : a systematic review and meta-analysis. BMC Cancer 18 : 438, 2018

12）Mitsuhashi A, et al : Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer. Ann Oncol 27 : 262-266, 2016

13）Chae-Kim J, et al : Outcomes of women treated with progestin and metformin for atypical endometrial hyperplasia and early endometrial cancer : a systematic review and meta-analysis. Int J Gynecol Cancer 31 : 1499-1505, 2021

14）Matsuo K, et al : Route-specific association of progestin therapy and concurrent metformin use in obese women with complex atypical hyperplasia. Int J Gynecol Cancer 30 : 1331-1339, 2020

15）Yang BY, et al : Metformin plus megestrol acetate compared with megestrol acetate alone as fertility-sparing treatment in patients with atypical endometrial hyperplasia and well-differentiated endometrial cancer : a randomised controlled trial. BJOG 127 : 848-857, 2020

16）Mitsuhashi A, et al : Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients. J Gynecol Oncol 30 : e90, 2019

17）Mitsuhashi A, et al : Medroxyprogesterone acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and endometrial carcinoma : trial protocol for a prospective, randomised, open, blinded-endpoint design, dose-response trial（FELICIA trial）. BMJ Open 10 : e035416, 2020